Impact of Endocrine Disorders on Autoimmune Diseases

Bromocriptine therapy: Review of mechanism of action, safety and tolerability

“…Studies have demonstrated that decreasing the prolactin production by dopaminergic stimulation may help ameliorate the condition of autoimmune patients, as dopamine potently inhibit the prolactin secretion by either directly influencing the pituitary gland or by stimulation of postsynaptic dopamine receptors in the hypothalamus, therefore, motivating the release of prolactin inhibitory factor 329,330 . In that instance, dopamine agonists such as bromocriptine have proven to be beneficial in various autoimmune diseases and even in controlling postpartum flare in lupus patients by representing promising effects in animal models as well as human subjects 331–335 . Bromocriptine, by blocking the dopamine receptor, constrains the central prolactin synthesis and in addition, also influences the B and T lymphocytes functions through the dopamine receptor.…”

“…329,330 In that instance, dopamine agonists such as bromocriptine have proven to be beneficial in various autoimmune diseases and even in controlling postpartum flare in lupus patients by representing promising effects in animal models as well as human subjects. [331][332][333][334][335] Bromocriptine, by blocking the dopamine receptor, constrains the central prolactin synthesis and in addition, also influences the B and T lymphocytes functions through the dopamine receptor. Bromocriptine has been revealed to decrease autoantibodies production and modify the expression of surface molecules and most likely downregulates autoimmune phenomena via induction of natural non-specific CD8 suppressor cells.…”